Clinical Trial Update: Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion [Phase 4]

View source ↗

Summary

Phase 4 study evaluating ketamine for depressive symptoms in patients undergoing lumbo-peritoneal shunt insertion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Major Depressive Disorder

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: Benha University | Conditions: Depression, Anxiety | Phase 4 | Status: COMPLETED